Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + cisplatin with sorafenib versus gemcitabine + cisplatin with placebo in advanced or metastatic urothelial carcinoma
2005-006098-29Phase 2Active
- Sponsor
- Universitätsmedizin Essen
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in transitional cell carcinoma of the bladder (TCC) comparing Gemcitabine + cisplatin + sorafenib with Gemcitabine + cisplatin + placebo (2 arms). Primary endpoints: Progression-free survival and Progression of disease. Started Sep 2006; status: active.
02
Drugs
sorafenib
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2005-006098-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-006098-29.